

INFORMATION RELEASE - 18 JUNE 2008

CBIO ANNOUNCES DOSING OF FIRST PATIENT IN PHASE IIA STUDY

Brisbane biotechnology company CBio Limited is pleased to announce that dosing has commenced in the first patient in its Phase Iia rheumatoid arthritis clinical trial.

This trial is designed to evaluate the safety and efficacy of the company's lead product, XToll[®], using a randomised, double-blind, placebo-controlled design in subjects with active rheumatoid arthritis despite current methotrexate treatment. Approximately 150 patients will be enrolled.

The study is CBio's first subcutaneous dosing clinical trial in patients with RA, and follows the intravenous dosing trial completed in 2006.

The study is being conducted throughout Australia and New Zealand.

Further information about the clinical trial can be found via the [Australia New Zealand Clinical Trials Registry](#), Ref: ACTRN12608000208303.

About CBio Limited

CBio Limited is an Australian unlisted public biopharmaceutical company established in 2001 to develop technologies for the treatment of autoimmune and inflammatory diseases. CBio's lead product XToll[®], or recombinant chaperonin 10 (Cpn10), is a modified version of the naturally occurring protein chaperonin 10.

For further information: www.cbio.com.au

Contact Information

Jason Yeates
Managing Director & CEO
CBio Limited
P: 07 3841 4844
E: jason.yeates@cbio.com.au

Dr Dennis Feeney
Executive Director & President Global Development & Licensing
CBio Limited
P: 07 3841 4844
E: dennis.feeney@cbio.com.au